BioNTech, Doer Biologics Enter License Agreement

Doer Biologics, a clinical stage biopharmaceutical company developing therapies for metabolic diseases and cancers, has entered into a license agreement with BioNTech, granting BioNTech a worldwide license to use one of its discoveries to research, develop, manufacture, and commercialize biotherapeutics against an undisclosed target. Doer Bio will receive an upfront payment and will be eligible for potential development, regulatory, and commercial milestones.
 
“This license agreement with BioNTech is a great demonstration of the enormous potential of Doer Bio’s platform technologies, which has been well validated by extensive preclinical research and ongoing clinical studies,” said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio.
 
“We are thrilled to work with BioNTech, a globally leading biopharmaceutical company, to translate our technologies and discoveries into novel therapies. We are looking forward to working with BioNTech to advance this innovation into clinic and ultimately benefit patients worldwide,” commented Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio.